papillary thyroid carcinoma semaglutide – – NUS Pathweb :: NUS Pathweb High aggressiveness of papillary thyroid
Description
Wang, Y., Liu, D., Zhang, T
16 luglio 2020;10(1):238
Conclusions Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks
Case Info GLP-1 Medications and NAION Vision Loss Lawsuit GLP-1 receptor agonists, widely prescribed to treat Type 2 diabetes and weight loss, have been linked to a higher risk of NAION
Ernest Asamoah, an endocrinologist with Community Health Network in Indianapolis
